Advertisement

Yield of Colonoscopy in Identification of Newly Diagnosed Desmoid-Type Fibromatosis with Underlying Familial Adenomatous Polyposis

  • Winan J. van Houdt
  • Iris H. Wei
  • Deborah Kuk
  • Li-Xuan Qin
  • Bhumika Jadeja
  • Anthony Villano
  • Meera Hameed
  • Samuel Singer
  • Aimee M. CragoEmail author
Colorectal Cancer

Abstract

Background

Desmoid-type fibromatosis can arise in patients with familial adenomatous polyposis (FAP), therefore patients with desmoids often undergo colonoscopy to rule out FAP. Because finding FAP is uncommon, we sought to define subsets of desmoid patients in whom colonoscopy frequently identified FAP.

Methods

Patients with desmoid-type fibromatosis were identified from surgery and pathology databases at a single institution, and information on colonoscopy and FAP diagnosis was collected retrospectively. CTNNB1 mutation status was defined by Sanger sequencing and digital polymerase chain reaction of archived specimens.

Results

Among 626 patients with desmoids, 26 were diagnosed with FAP. In 20 patients, FAP diagnosis predated the desmoid diagnosis. Among patients without prior FAP diagnosis, 161 underwent colonoscopy, which identified only six cases of FAP (diagnostic yield 3.7%). Yields were substantially higher among patients with four characteristics: age < 40 years (11% yield), intra-abdominal or retroperitoneal tumors (5.4%), multifocal disease (29%), and family history (8%) (all p < 0.001). All cases of FAP were detected in patients younger than 40 years of age and with at least one of the other three characteristics. CTNNB1 mutation status was available in 82 patients with known FAP status. None of the 61 patients with CTNNB1 mutations were diagnosed with FAP, while 7 of the 21 patients with no CTNNB1 mutation detected (24%) were FAP patients.

Conclusions

Patients with desmoid-type fibromatosis and undiagnosed FAP generally have multiple risk factors, which may be used to selectively recommend colonoscopic screening. Routine CTNNB1 sequencing may also rule out FAP and allow for deferral of colonoscopy.

Notes

Acknowledgment

The authors acknowledge the use of the Integrated Genomics Operation Core, also funded by the National Cancer Institute (NCI) Cancer Center Support Grant, as well as Cycle for Survival and the Marie-Josée and Henry R. Kravis Center for Molecular Oncology. They thank Janet Novak, Ph.D., and Jessica Moore, MS, of MSKCC for editing the manuscript.

Funding

This work was supported by the American Cancer Society (MRSG-15-064-01-TBG, to AC), The Kristen Ann Carr Foundation (AC), Alicia and Corey Pinkston (AC and IHW), the Dutch Cancer Society (NKI 2014-6651, to WvH), the National Cancer Institute through the SPORE in Soft Tissue Sarcoma Grant (P50-CA140146, to SS, LQ, and MH), Surgical Oncology Research Training Grant (4T32CA009501-29, to AV), and the MSKCC Institutional Cancer Center Core Grant (P30-CA008748).

Compliance with Ethical Standards

Conflict of interest

Winan J. van Houdt, Iris H. Wei, Deborah Kuk, Li-Xuan Qin, Bhumika Jadeja, Anthony Villano, Meera Hameed, Samuel Singer, and Aimee M. Crago have no conflicts of interest to report.

Disclosures

No disclosures.

Supplementary material

10434_2018_7138_MOESM1_ESM.docx (117 kb)
Supplementary material 1 (DOCX 116 kb)

References

  1. 1.
    Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg. 1986;151:230–7.CrossRefGoogle Scholar
  2. 2.
    Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, et al. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011;129:256–61.CrossRefGoogle Scholar
  3. 3.
    Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18:6615–20.CrossRefGoogle Scholar
  4. 4.
    Crago AM, Chmielecki J, Rosenberg M, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015;54:606–15.CrossRefGoogle Scholar
  5. 5.
    Li M, Cordon-Cardo C, Gerald WL, Rosai J. Desmoid fibromatosis is a clonal process. Hum Pathol. 1996;27:939–43.CrossRefGoogle Scholar
  6. 6.
    Wu C, Amini-Nik S, Nadesan P, et al. Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. Cancer Res. 2010;70:7690–8.CrossRefGoogle Scholar
  7. 7.
    Giarola M, Wells D, Mondini P, et al. Mutations of adenomatous polyposis coli (APC) gene are uncommon in sporadic desmoid tumours. Br J Cancer. 1998;78:582–7.CrossRefGoogle Scholar
  8. 8.
    Heiskanen I, Jarvinen HJ. Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment. Int J Colorectal Dis. 1996;11:157–62.CrossRefGoogle Scholar
  9. 9.
    Lynch HT, Lynch JF, Lynch PM, Attard T. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Fam Cancer. 2008;7:27–39.CrossRefGoogle Scholar
  10. 10.
    Nugent KP, Spigelman AD, Phillips RK. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum. 1993;36:1059–62.CrossRefGoogle Scholar
  11. 11.
    Arvanitis ML, Jagelman DG, Fazio VW, et al. Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum. 1990;33:639–42.CrossRefGoogle Scholar
  12. 12.
    Jones IT, Jagelman DG, Fazio VW, et al. Desmoid tumors in familial polyposis coli. Ann Surg. 1986;204:94–97.CrossRefGoogle Scholar
  13. 13.
    Bisgaard ML, Fenger K, Bulow S, et al. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat. 1994;3:121–5.CrossRefGoogle Scholar
  14. 14.
    Colombo C, Foo WC, Whiting D, et al. FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center. Histol Histopathol. 2012;27:641–9.Google Scholar
  15. 15.
    Koskenvuo L, Peltomaki P, Renkonen-Sinisalo L, et al. Desmoid tumor patients carry an elevated risk of familial adenomatous polyposis. J Surg Oncol. 2016;113:209–12.CrossRefGoogle Scholar
  16. 16.
    Fallen T, Wilson M, Morlan B, Lindor NM. Desmoid tumors: a characterization of patients seen at Mayo Clinic 1976–1999. Fam Cancer. 2006;5:191–4.CrossRefGoogle Scholar
  17. 17.
    Soravia C, Berk T, McLeod RS, Cohen Z. Desmoid disease in patients with familial adenomatous polyposis. Dis Colon Rectum. 2000;43:363–9.CrossRefGoogle Scholar
  18. 18.
    Campos FG, Martinez CA, Novaes M, et al. Desmoid tumors: clinical features and outcome of an unpredictable and challenging manifestation of familial adenomatous polyposis. Fam Cancer. 2015;14:211–9.CrossRefGoogle Scholar
  19. 19.
    Bandipalliam P, Balmana J, Syngal S. Comprehensive genetic and endoscopic evaluation may be necessary to distinguish sporadic versus familial adenomatous polyposis-associated abdominal desmoid tumors. Surgery. 2004;135:683–689.CrossRefGoogle Scholar
  20. 20.
    Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518–27.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Winan J. van Houdt
    • 1
    • 2
  • Iris H. Wei
    • 3
    • 4
  • Deborah Kuk
    • 5
  • Li-Xuan Qin
    • 5
  • Bhumika Jadeja
    • 1
  • Anthony Villano
    • 1
  • Meera Hameed
    • 6
  • Samuel Singer
    • 1
    • 4
  • Aimee M. Crago
    • 1
    • 4
    Email author
  1. 1.Sarcoma Biology Laboratory and Sarcoma Disease Management Team, Sarcoma Disease Management Program, Department of SurgeryMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Surgical OncologyThe Netherlands Cancer InstituteAmsterdamThe Netherlands
  3. 3.Colorectal Service, Department of SurgeryMemorial Sloan Kettering Cancer CenterNew YorkUSA
  4. 4.Department of SurgeryWeill Cornell Medical CollegeNew YorkUSA
  5. 5.Department of BiostatisticsMemorial Sloan Kettering Cancer CenterNew YorkUSA
  6. 6.Department of PathologyMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations